Biomarkers in Blood Samples From Patients With Acute Myeloid Leukemia

NCT01385150 | Completed

• 2 other identifiers: CDR0000702952ECOG-E1900T8
• Study Type: observational
• Target: 220
• Locations: 0 countries
• Sites: N/A

Brief Summary

RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors identify and lean more about biomarkers related to cancer. PURPOSE: This research study is studying biomarkers in blood samples from patients with acute myeloid leukemia.

Conditions

Leukemia

Keywords

adult acute myeloid leukemia with 11q23 (MLL) abnormalities; adult acute myeloid leukemia with inv(16)(p13;q22); adult acute myeloid leukemia with t(16;16)(p13;q22); adult acute myeloid leukemia with t(8;21)(q22;q22); untreated adult acute myeloid leukemia; adult acute basophilic leukemia; adult acute eosinophilic leukemia; adult erythroleukemia (M6a); adult pure erythroid leukemia (M6b); adult acute minimally differentiated myeloid leukemia (M0); adult acute monoblastic leukemia (M5a); adult acute monocytic leukemia (M5b); adult acute myeloblastic leukemia with maturation (M2); adult acute myeloblastic leukemia without maturation (M1); adult acute myelomonocytic leukemia (M4)

Outcome Measures

Primary Outcomes (1)

• Absence of serum 2HG in all samples without an IDH mutation

  1 day

Secondary Outcomes (1)

• Relationship between 2HG level and survival outcomes

  1 day

Interventions

mutation analysis GENETIC

protein analysis GENETIC

laboratory biomarker analysis OTHER

liquid chromatography OTHER

mass spectrometry OTHER

Eligibility Criteria

• Age: 17 Years - 60 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64)
• Sampling Method: Non-Probability Sample

Study Population

Samples from patients enrolled on E1900 from whom samples were submitted for research

DISEASE CHARACTERISTICS: * Morphologically confirmed acute myeloid leukemia (AML) * Newly diagnosed with AML * Serum samples from patients enrolled on the ECOG-1900 clinical trial between 2002 and 2008 * Patients with or without isocitrate dehydrogenase (IDH) mutations PATIENT CHARACTERISTICS: * Not specified PRIOR CONCURRENT THERAPY: * Received 2 different doses of standard induction chemotherapy on ECOG-1900

Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.

Sponsors & Collaborators

• Eastern Cooperative Oncology Group: lead
• National Cancer Institute (NCI): collaborator

MeSH Terms

Conditions

Leukemia; Congenital Abnormalities; Leukemia, Basophilic, Acute; Leukemia, Eosinophilic, Acute; Leukemia, Erythroblastic, Acute; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute

Interventions

Chromatography, Liquid; Mass Spectrometry

Condition Hierarchy (Ancestors)

Neoplasms by Histologic Type; Neoplasms; Hematologic Diseases; Hemic and Lymphatic Diseases; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Leukemia, Myeloid; Myeloproliferative Disorders; Bone Marrow Diseases

Intervention Hierarchy (Ancestors)

Chromatography; Chemistry Techniques, Analytical; Investigative Techniques

Study Officials

• Courtney DiNardo, MD

  Abramson Cancer Center at Penn Medicine

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: RETROSPECTIVE
• Sponsor Type: NETWORK
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 28, 2011
• First Posted: June 29, 2011
• Study Start: January 3, 2012
• Primary Completion: February 3, 2012
• Study Completion: February 3, 2012
• Last Updated: May 19, 2017

Record last verified: 2017-05